The occurrence of neuroleptic malignant syndrome in patients on antipsychotic therapy and factors influencing its development ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

Glioblastoma is an extremely aggressive brain tumour that is currently incurable Cancer doctors can increase their patients life expectancy with surgeries ra ...

There is no correlation between high-density lipoprotein cholesterol (HDL-C) levels and a patient's risk for developing ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...

A CHEAP drug that’s already on the market could be effective against deadly brain tumours, scientists say. Glioblastomas are ...

Research in cell cultures and mice demonstrates an antidepressant called vortioxetine may be effective in combating glioblastomas.

Vortioxetine, an antidepressant, shows promise against glioblastoma in lab tests conducted by ETH Zurich, leading to ...

Data from the federal government shows that Mississippi consistently ranks in the top five in the nation for its rates of ...

A new study in the Journal of Child and Adolescent Psychopharmacology estimates the incidence of neuroleptic malignant ...